VEGFA and non-small cell lung carcinoma: Antiangiogenic drugs, including monoclonal antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptors (VEGFRs), such as bevacizumab [5, 6], and small-molecule tyrosine kinase inhibitors (TKIs) targeting multiple angiogenic pathways, such as anlotinib [7, 8] and apatinib [9, 10], have shown antitumour effects in NSCLC.